New CSFD team targets opioid response
The Targeted Opioid Response and Medication Assisted Treatment (TOR-MAT) team is comprised of a civilian paramedic and a behavioral health navigator who provide intervention and medication for individuals who have an opiate dependence/addiction.
The new program is the first of its kind in Colorado and was placed in service on Monday, Feb. 24.
'Adding this new team will not only help a vulnerable population in our community who often don't get the right resources for their needs but will help better the lives of the people we humbly serve every day,' said Fire Chief Randy Royal. 'Innovation is always at the forefront of our minds and this new program is a shining example of that. I look forward to seeing the lives that will undoubtedly be touched and made better off by this program.'
The team will take referrals from the community as space allows, however, most will be generated from follow-ups from 911 Opioid Overdose calls for service.
Personnel from the program will make contact with patients within 72 hours to assess opiate withdrawal status and initiate voluntary Medical Assisted Treatment with Buprenorphine strips, an opioid medication used to replace opioids an individual may be using.
When taken correctly, Buprenorphine presents withdrawal symptoms and reduces drug cravings without causing the person to feel high or sleepy. This lowers the harms associated with opioid misuse and gives people who are addicted to opioids a chance to stabilize their lives.
The program will also facilitate referrals to local Buprenorphine clinics and will provide Narcan Kits when appropriate. The program will also educate patients, family, and friends on kit usage.
The goal is to bridge the gap in services that often happen after someone experiences an overdose or suffers from opioid addiction by offering medication-assisted treatment and connection to community resources.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
07-08-2025
- Yahoo
Seniors say this 'effective and safe' Amazon bath mat helps prevent falls in the shower — and it's 50% off
Shoppers say it has a "cushion-like feeling" and call it the "best shower mat ever." It only takes a quick second to fall and injure yourself, which is why it's essential to prevent unnecessary slips. According to HealthLink BC, thousands of older adults fall and hurt themselves every year. The organization recommends installing non-skid mats inside your shower or tub to help prevent unexpected injuries. The Gorilla Grip Patented Bath Mat is currently 50 per cent off on Amazon Canada, bringing its price down to $23. It has more than 87,000 ratings and shoppers say it's "effective and safe." The only catch? It's a lightning deal, so you'll want to move fast. If you're interested, keep scrolling to see more about the deal and what customers have to say about the product. The details This textured, plastic bath mat has hundreds of suction cups that adhere to the bottom of your tub and shower to keep it firmly in place. It also has dozens of drainage holes that easily allow water to flow under the mat, helping to prevent stagnant water from sitting on the mat and in your tub. The mat itself is 35 x 16 inches, and it comes in 20 different colour options, including transparent and opaque choices. If it's starting to look a little dirty, all you need to do is throw it in your washing machine and then let it air dry. What reviewers are saying ⭐ 4.5/5 stars 🛍️ 87,000+ reviews 🏅"This bath mat is fantastic. It grips the tub securely to avoid slipping." Gorilla Grip Patented Bath Mat $20 $40 at Amazon Someone called the product the "best shower mat ever" and said they'd repurchase it if needed. Another said it's "incredibly effective" and shared it has a "cushion-like feeling." Other shoppers also said it's "comfy on the feet" and also comfortable to sit on, noting they "feel much safer" when dealing with the slippery surfaces. However, some users say it could use "a little more padding," while others say the size is awkward for their particular shower or tub — all things to keep in mind before purchasing. The verdict With more than 87,000 reviews, shoppers say this Amazon's Choice bath mat is comfortable and effective. Most importantly, it makes them feel safer in the shower and helps prevent shower- and bath-related injuries. However, be sure to take down the measurements of your tub or shower before ordering.
Time Business News
06-08-2025
- Time Business News
How Long Suboxone Remains in Your System and the Withdrawal Timeline Explained
Suboxone is a pharmaceutical formulation combining buprenorphine and naloxone. Primarily used in the treatment of opioid dependence, it binds to the same receptors targeted by drugs like heroin or oxycodone. Buprenorphine, a partial opioid agonist, mitigates cravings and withdrawal symptoms without producing a significant euphoric high. Naloxone, an opioid antagonist, is added to deter intravenous misuse. This synergistic blend creates a ceiling effect that limits opioid intoxication, making it an effective maintenance therapy. However, due to its long-acting nature, the drug lingers in the system longer than many realize, raising questions about detox duration and withdrawal experiences. Understanding how long a substance remains active in the body is essential for both medical and personal reasons. Typically, Suboxone—a combination of buprenorphine and naloxone—has a half-life that allows it to stay in your system for an extended period. How Long does suboxone stay in your system depends on several factors including dosage, frequency of use, metabolism, and liver function. On average, traces may be detectable in urine for up to 14 days, though the effects usually taper off within a few days. Always consult a healthcare provider for personalized guidance related to treatment or testing. The body's metabolism plays a crucial role in processing and eliminating Suboxone. Individuals with a high basal metabolic rate tend to clear substances more rapidly. This is because enzymes in the liver—particularly cytochrome P450 3A4—break down buprenorphine. Variations in this enzymatic activity create noticeable discrepancies in drug clearance among users. Chronic use leads to accumulation in fatty tissues, extending the drug's half-life. Someone using Suboxone daily for months or years will take longer to eliminate it compared to a person on a short-term taper. The dosage also matters; higher doses can prolong detection and intensify withdrawal symptoms. The liver, as the central detox organ, is essential in the metabolism of Suboxone. Impaired hepatic function can substantially delay drug clearance. Additionally, genetic polymorphisms in metabolizing enzymes can alter the pharmacokinetics of buprenorphine, making the elimination process either faster or slower depending on one's unique biochemical blueprint. Urinalysis is the most common method for detecting Suboxone. Buprenorphine can be found in urine for up to 7–10 days after the last dose, depending on usage patterns and metabolism. Naloxone, due to its short half-life, is usually undetectable after 48 hours. In blood, Suboxone typically remains detectable for up to 2–5 days. Because blood concentrations reflect current intoxication rather than long-term exposure, this method is often used in clinical settings rather than routine screening. Saliva tests can detect Suboxone within 24–96 hours, making them suitable for recent use assessment. Hair follicle testing, though less common, can trace Suboxone for up to 90 days, providing a long-term window into substance use history. Buprenorphine has a notably long half-life ranging from 24 to 42 hours, which contributes to its prolonged presence in the body. Complete systemic elimination can take up to 8–10 days after the final dose. Naloxone, by contrast, has a short half-life of just 2–12 hours. The extended half-life of buprenorphine allows for once-daily dosing but also makes withdrawal a slow, gradual process compared to shorter-acting opioids. Typically begins 24–72 hours after the last dose. Symptoms include anxiety, muscle aches, runny nose, and insomnia. These are the harbingers of withdrawal, often subtle at first but increasingly persistent. From day 3 to day 7, symptoms escalate. Gastrointestinal distress, intense cravings, chills, and irritability dominate. This stage is the most physically taxing, and many relapses occur here without medical or emotional support. After the acute phase, symptoms may persist for weeks or even months. Known as PAWS, this stage includes lingering psychological symptoms such as depression, mood swings, and anhedonia. While not as physically intense, the emotional toll can derail recovery if not properly managed. Tapering under medical supervision is the safest method for discontinuing Suboxone. Gradual dose reduction allows the body to recalibrate opioid receptor activity. Clonidine, anti-nausea agents, and sleep aids may be prescribed to ease symptoms. Psychological support—via therapy, group counseling, or 12-step programs—is critical during and after the taper. Nutritional interventions, hydration, and light exercise also foster physiological stability. In some cases, long-term use of buprenorphine at reduced dosages may be recommended as part of a harm-reduction approach. Suboxone's extended presence in the body offers therapeutic benefits but complicates the withdrawal process. Individual factors heavily influence how long Suboxone remains in the system and the intensity of its exit. Understanding the timeline, preparing for each stage, and embracing a multi-dimensional support system can transform a daunting process into a manageable journey. Recovery demands resilience, informed choices, and time—three pillars that, when combined, lay the foundation for sustained sobriety. TIME BUSINESS NEWS
Business Upturn
01-08-2025
- Business Upturn
FOXO TECHNOLOGIES INC.'S BIG SOUTH FORK MEDICAL CENTER COMPLETES PERFORMANCE NETWORK AGREEMENT WITH COVENANT HEALTH TO PROVIDE SWING BED SERVICES
WEST PALM BEACH, FLORIDA, Aug. 01, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (NYSE American: FOXO) ('FOXO' or the 'Company') today announced that its critical access designated rural hospital, Big South Fork Medical Center located in Oneida, Tennessee, has completed a Performance Network Agreement with Covenant Health to join their performance network as a provider of swing bed services. Covenant Health is a large, muti-facility hospital network serving greater Knoxville and East Tennessee. Patients who no longer meet acute care admission criteria are frequently in need of post-acute care to enhance their recovery. Big South Fork Medical Center is well positioned to provide swing bed services to a number of patients needing post-acute care, which will facilitate patients returning to their communities and being closer to their family during their recovery periods. Hal Leftwich, CEO of Big South Fork Medical Center noted, 'This agreement is an attestation to the services we provide and our hospital's proximity to patient homes in this and surrounding communities which make us an attractive option for many patients in need of post-acute care.' 'Being part of Covenant Health's performance network is consistent with our organic growth strategy of increasing net revenues at the hospital,' stated Seamus Lagan, Chief Executive Officer of parent company, FOXO Technologies Inc. About FOXO Technologies Inc. ('FOXO') FOXO owns and operates three subsidiaries. Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), a critical access designated (CAH) hospital in East Tennessee. Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services for MAT and OBOT Programs. FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries. For more information about FOXO, visit Forward-Looking Statements This press release contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the FOXO's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO's business; the ability to implement FOXO's business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; the enforceability of FOXO's intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO's most recent reports on Forms 10-K and 10-Q, particularly the 'Risk Factors' sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Contact: Sebastien Sainsbury [email protected] (561) 485-0151 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
